A Study of LY3154207 in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Participants

In brief

This study involves single doses of LY3154207 and will evaluate the effects of LY3154207 on the body. There will be 3 parts to this study. Part A will test single increasing doses of LY3154207 and will last approximately 7 weeks for each participant. Each participant will receive two doses of LY3154207, if part A is completed. Part B will test a single dose of LY3154207 and will last approximately 5 weeks for each participant. Part B includes collecting fluid from the spinal column to measure levels of LY3154207. Part C will include a single dose of LY3154207 given alone and then a second dose given along with itraconazole to look for change in LY3154207 levels. Part C will last about 3 weeks for each participant. Participants may only enroll in 1 of the 3 parts of the study.

Key facts

Study ID: NCT02365571
Run by: Eli Lilly and Company
People needed: 64
Starts: 2015-02-01
Expected to finish: 2015-05-01
Last updated by the study team: 2015-06-11

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

Overtly healthy males or females, as determined by medical history and physical examination
Female participants not of child-bearing potential
Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Have given written informed consent
Have a body mass index (BMI) of 18 to 35 kilograms per square meter (kg/m\^2)

You may not qualify if…

Part B only: Have medical or surgical conditions in which lumbar puncture is contraindicated
Part C only: Have known allergy or contraindications to itraconazole

Where it is running

PRA Health Sciences — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.